CA2814150A1 - Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes - Google Patents

Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes Download PDF

Info

Publication number
CA2814150A1
CA2814150A1 CA2814150A CA2814150A CA2814150A1 CA 2814150 A1 CA2814150 A1 CA 2814150A1 CA 2814150 A CA2814150 A CA 2814150A CA 2814150 A CA2814150 A CA 2814150A CA 2814150 A1 CA2814150 A1 CA 2814150A1
Authority
CA
Canada
Prior art keywords
tumor
cancer patient
otls
otl
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2814150A
Other languages
English (en)
French (fr)
Inventor
Sven Olek
Tim Schwachula
Udo Baron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Precision for Medicine GmbH
Original Assignee
Epiontis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epiontis GmbH filed Critical Epiontis GmbH
Publication of CA2814150A1 publication Critical patent/CA2814150A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2814150A 2010-10-08 2011-10-10 Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes Abandoned CA2814150A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10187046 2010-10-08
EP10187046.7 2010-10-08
PCT/EP2011/067660 WO2012045888A1 (en) 2010-10-08 2011-10-10 Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes

Publications (1)

Publication Number Publication Date
CA2814150A1 true CA2814150A1 (en) 2012-04-12

Family

ID=44802051

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2814150A Abandoned CA2814150A1 (en) 2010-10-08 2011-10-10 Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes

Country Status (5)

Country Link
US (1) US20130260378A1 (enExample)
EP (1) EP2625288B1 (enExample)
JP (1) JP6010037B2 (enExample)
CA (1) CA2814150A1 (enExample)
WO (1) WO2012045888A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715829A (zh) * 2016-05-16 2019-05-03 迪莫·迪特里希 一种评估预后和预测恶性疾病患者对免疫治疗的反应的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201221133D0 (en) 2012-11-23 2013-01-09 Epiontis Gmbh Epigenetic method for the identification of subpopulations of CD8 and T lympocytes, in particular CD8 alpha and beta T lymphocytes
GB201516971D0 (en) * 2015-09-25 2015-11-11 Epiontis Gmbh MVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
GB201516972D0 (en) * 2015-09-25 2015-11-11 Epiontis Gmbh LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells
US11685955B2 (en) 2016-05-16 2023-06-27 Dimo Dietrich Method for predicting response of patients with malignant diseases to immunotherapy
JP7061342B2 (ja) * 2018-03-14 2022-04-28 学校法人 愛知医科大学 エフェクター制御性ｔ細胞の検出及び調製
DE102018116353B4 (de) * 2018-07-05 2020-06-10 Epiontis Gmbh Verfahren zum Nachweis und zur Zählung epigenetischer Immunzellen in humanen Blutproben für Immundiagnostik und Neugeborenen-Screening
WO2021077063A1 (en) * 2019-10-18 2021-04-22 Washington University Methods and systems for measuring cell states
WO2024254366A1 (en) 2023-06-09 2024-12-12 Dow Global Technologies Llc Method for producing corrugated laminated panels

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002171973A (ja) 2000-12-07 2002-06-18 Univ Tokyo Ｄｎａメチル化パターンによる細胞の同定法
AU2003285586A1 (en) 2002-12-03 2004-06-23 Medical Research Council Regulatory t-cells
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
DK1826279T3 (da) 2006-02-28 2011-09-05 Charite Universitaetsmedizin Detektering og kvalitetskontrol af regulatoriske t-celler vha. DNA-metyleringsanalyse af FoxP3--genet
EP2141245A1 (en) * 2008-07-03 2010-01-06 Ivana Türbachova DNA methylation analysis of regulatory T cells through DNA-methylation analysis of the TSDR region of the gene foxP3
DK2199411T3 (en) * 2008-12-16 2015-08-03 Epiontis Gmbh Epigenetic markers for the identification of CD3-positive T lymphocytes

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715829A (zh) * 2016-05-16 2019-05-03 迪莫·迪特里希 一种评估预后和预测恶性疾病患者对免疫治疗的反应的方法
CN109715829B (zh) * 2016-05-16 2022-07-08 迪莫·迪特里希 一种评估预后和预测恶性疾病患者对免疫治疗的反应的方法

Also Published As

Publication number Publication date
EP2625288B1 (en) 2016-05-25
JP2013544502A (ja) 2013-12-19
WO2012045888A1 (en) 2012-04-12
US20130260378A1 (en) 2013-10-03
JP6010037B2 (ja) 2016-10-19
EP2625288A1 (en) 2013-08-14

Similar Documents

Publication Publication Date Title
EP2625288B1 (en) Method for determining cancer patient survival based on analyzing tumor-infiltrating overall t-lymphocytes
Clarke et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
AU2012260785B2 (en) Biomarkers for lung cancer
Gorovets et al. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma
Hrašovec et al. TMEM25 is a candidate biomarker methylated and down‐regulated in colorectal cancer
EP2670861B1 (en) Markers of melanoma and uses thereof
Samadder et al. Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women
EP2007874A2 (en) Propagation of primary cells
Lian et al. Screening of significantly hypermethylated genes in breast cancer using microarray-based methylated-CpG island recovery assay and identification of their expression levels
WO2008083251A2 (en) Dna methylation markers based on epigenetic stem cell signatures in cancer
Eggers et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma
Heesch et al. Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia
EP3140420B1 (en) Breast cancer epigenetic markers useful in anthracycline treatment prognosis
WO2010000474A1 (en) Dna methylation analysis of regulatory t cells through dna-methylation analysis of the tsdr region of the gene foxp3
Truong et al. BRCA1 promoter hypermethylation signature for early detection of breast cancer in the Vietnamese population
Liu et al. TERT promoter mutations and methylation for telomerase activation in urothelial carcinomas: new mechanistic insights and clinical significance
Wang et al. ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndrome
EP2855705B1 (en) Method of diagnosing cancer comprising detection of the methylation signature in the htert promoter
CN111440863B (zh) Kazn基因甲基化检测试剂在制备结直肠癌预后诊断试剂中的应用
WO2008143896A1 (en) Methylation markers for prostate cancer and methods of use
Ma et al. Methylation-independent CRIP1 expression is a potential biomarker affecting prognosis in cytogenetically normal acute myeloid leukemia
WO2012052844A1 (en) Methods and biomarkers for detection of bladder cancer
JP2022548993A (ja) Ｄｎａメチル化異常を用いた免疫抗癌治療反応性予測方法
Hütter et al. Epigenetic regulation of PAX5 expression in acute T-cell lymphoblastic leukemia
JP2015177745A (ja) 肺癌の検査方法

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171011